Medical Research Laboratory, Clinical Institute of Medicine, Aarhus University Hospital
Aarhus, 8000, Denmark
NCT Number: NCT01762540
The main purpose of the trial is to advance our knowledge on the possible mechanism underlying the catabolic effects of long-term treatment with glucocorticoid.
Looking for future studies?
Notify Me20 year–30 year
Male
Interventional
Phase 2
Aarhus, 8000, Denmark
Long-term treatment with glucocorticoid induces a general state of catabolism and increases insulin resistance. The underlying mechanisms are insufficiently characterized, however glucocorticoid induced changes of Growth Hormone (GH) and the Insulin-like growth factor I (IGF-I) appear to be of outmost importance.
We wish to investigate the mechanism behind glucocorticoid induced catabolism and insulin resistance.
More specific we wish to investigate:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Prednisolone 37.5 mg x1 for 5 days
Other names: Prednisolone
Placebo
Other names: Placebo
Time frame: day 1, 3 and 5
Blood-test before (day 1) during (day 3) and at the end (day 5) of placebo/prednisolone treatment.
Time frame: day 5
Tissue biopsy on day 5.
Time frame: Day 5
Hyperinsulinemic euglycemic clamp on day 5.
University of Aarhus
Other
Glucocorticoid Induced Inhibition of IGF-I Activity: Exploring Underlying Mechanisms.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07618663
Diabetes Mellitus, Endocrine System Diseases
Lahore, Shaikhupura, Pakistan
View Trial DetailsNCT03919877
Diabetes Mellitus, Diabetes Mellitus, Type 2
Stanford, California, United States
View Trial DetailsNCT07194772
Glucose Homeostasis, Glucose Intolerance
Ottawa, Ontario, Canada
View Trial DetailsNCT06920641
Communicable Diseases, Disease Attributes
Toronto, Ontario, Canada
View Trial Details